CDKN2A and melanoma: The CDKN2A mutation occurs in approximately 20%–40% of high‐risk families (Rossi et al., 2019), accounting for 1%–2% of melanomas overall, a condition known as the familial melanoma syndrome (FMS) (Potrony et al., 2015).